<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02563964</url>
  </required_header>
  <id_info>
    <org_study_id>NL51875.068.14 / METC 152007</org_study_id>
    <nct_id>NCT02563964</nct_id>
  </id_info>
  <brief_title>Vulnerable Plaque Imaging in NSTEMI</brief_title>
  <acronym>CULPRIT</acronym>
  <official_title>Characterizing Vulnerable Plaques in Non-ST-Elevation Myocardial Infarction Using 18F-NaF Positron Emission Tomography - Cardiac Magnetic Resonance Imaging: A Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myocardial infarction (MI) frequently recurs after non-ST elevation MI (NSTEMI) that may be
      related to insufficient vulnerable plaque identification using invasive coronary angiography.
      Furthermore, the natural behaviour of vulnerable plaques in NSTEMI over time and their
      relation with biomarkers need further exploration. More accurate identification and assessing
      long-term behaviour of vulnerable plaques may improve therapeutic strategies and clinical
      outcome. The investigators hypothesize that fully integrated 18Fluoride Sodium-Fluoride
      (18F-NaF) Positron Emission Tomography/Cardiac Magnetic Resonance imaging (PET/CMR) increases
      the ability to detect vulnerable plaques as compared to coronary angiography.

      This prospective study in 33 consecutive patients with NSTEMI aims to:

        1. Compare coronary vulnerable plaque detection between 18F-NaF PET/CMR and invasive
           coronary angiography,

        2. Investigate the correlation of coronary vulnerable plaques using 18F-NaF PET with
           myocardial infarction using CMR, both at baseline and during follow-up,

        3. Examine systemic arterial 18F-NaF-uptake using PET/CMR and their relation with systemic
           events (cerebrovascular accidents, transient ischemic attacks, or peripheral arterial
           disease), and

        4. Examine the relation between vulnerable plaques and plasma biomarkers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>The frequency of coronary vulnerable plaques in non-ST-elevation myocardial infarction (NSTEMI) using 18Fluoride Sodium-Fluoride (18F-NaF) Positron Emission Tomography/Cardiac Magnetic Resonance (PET/CMR).</measure>
    <time_frame>0 to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The frequency of coronary vulnerable plaques in NSTEMI using routine invasive coronary angiography.</measure>
    <time_frame>0 to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The location of vulnerable plaques within the coronary arteries using 18F-NaF PET at baseline and follow-up.</measure>
    <time_frame>0 to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Based on the AHA 17-segment model, the segmental location of MI using CMR at baseline and follow-up.</measure>
    <time_frame>0 to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequency of systemic vulnerable plaques as assessed with 18F-NaF PET/CMR at baseline and follow-up.</measure>
    <time_frame>0 to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial serum concentrations of biomarkers of plaque vulnerability and myocardial injury at baseline and follow-up.</measure>
    <time_frame>0 to 6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Myocardial Ischemia</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biomarkers
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Thirty-three patients, 18-85 years old and admitted with non-ST elevation myocardial
        infarction (NSTEMI). After informed consent, patients wil receive standard, guideline-based
        clinical care that includes invasive coronary angiography. Plasma biomaker will be sampled
        serially, and a comprehensive Sodium 18F-Fluoride Positron Emission Tomography/Cardiac
        Magnetic Resonance imaging (18F-NaF PET/CMR) will be performed at baseline (&lt;72 hours) and
        at 6 months, or earlier when patients suffer recurrent myocardial infarction &lt; 6months.
        Patients will be followed for one year during regular outpatient clinic visits.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prolonged symptoms suspected of cardiac origin (angina pectoris or angina equivalent),
             and presentation on the cardiac emergency department &lt;24 hours after symptom onset

          -  Elevated levels of high-sensitivity troponin T (&gt;14ng/L; initial blood sample at
             presentation or a second sample 3 hours after presentation)

          -  Only patients scheduled for invasive coronary angiography

          -  Age 18 years - 85 years

          -  Mentally competent

          -  Informed written consent

        Exclusion Criteria:

          -  Conservatively managed patients who are not scheduled for invasive coronary
             angiography

          -  Refractory angina or on-going severe ischemia requiring immediate invasive coronary
             angiography

          -  Patients requiring invasive coronary angiography &lt; 24 hours after admission

          -  Hemodynamic instability and cardiogenic shock (mean arterial pressure &lt; 60 mmHg)

          -  Severe heart failure (Killip Class ≥ III)

          -  ST elevation myocardial infarction (ST-elevation in 2 contiguous leads: ≥0.2mV in men
             or ≥0.15 mV in women in leads V2-V3 and/or ≥0.1 mV in other leads or new left bundle
             branch block)

          -  Chest pain highly suggestive of non-cardiac origin (as judged by the cardiac emergency
             department physician/cardiologist):

          -  (Suspicion of) acute aortic dissection, acute pulmonary embolism, acute
             peri-myocarditis

          -  Life threatening arrhythmias on the cardiac emergency department or prior to
             presentation (sustained ventricular tachycardia, repetitive non-sustained ventricular
             tachycardia, ventricular fibrillation, sino-artial or atrio-ventricular block)

          -  Atrial fibrillation with ventricular rate ≥100 beats per minute (bpm)

          -  Tachycardia (≥100/bpm)

          -  Angina pectoris secondary to anaemia (&lt;5.6 mmol/L), untreated hyperthyroidism, or
             severe hypertension (&gt;200/110 mmHg)

          -  More than mild aortic and mitral valve calcification or stenosis by latest
             echocardiography

          -  Pregnancy

          -  Breast feeding women

          -  Life expectancy &lt;2 years (malignancy, etc.)

          -  Refusal of data storage until 15 years after end of study

          -  Participation in another investigational study that has not reached its primary
             endpoint

          -  Contraindications to cardiac magnetic resonance imaging
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joachim Wildberger, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harry J. Crijns, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sebastiaan C. Bekkers, MD, PhD</last_name>
    <phone>+31-43-3875098</phone>
    <email>s.bekkers@mumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastiaan C Bekkers, MD, PhD</last_name>
      <phone>+31-43-3875098</phone>
      <email>s.bekkers@mumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Bas Kietselaer, MD, PhD</last_name>
      <phone>+31-43-3875093</phone>
      <email>b.kietselaer@mumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Harry J Crijns, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joachim Wildberger, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastiaan C Bekkers, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastian A Streukens, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yvonne Cauteren van, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martijn W Smulders, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005 Jun 28;111(25):3481-8. Review.</citation>
    <PMID>15983262</PMID>
  </reference>
  <reference>
    <citation>Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000 May;20(5):1262-75. Review.</citation>
    <PMID>10807742</PMID>
  </reference>
  <reference>
    <citation>Cutlip DE, Chhabra AG, Baim DS, Chauhan MS, Marulkar S, Massaro J, Bakhai A, Cohen DJ, Kuntz RE, Ho KK. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation. 2004 Sep 7;110(10):1226-30. Epub 2004 Aug 30.</citation>
    <PMID>15337693</PMID>
  </reference>
  <reference>
    <citation>Glaser R, Selzer F, Faxon DP, Laskey WK, Cohen HA, Slater J, Detre KM, Wilensky RL. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation. 2005 Jan 18;111(2):143-9. Epub 2004 Dec 27.</citation>
    <PMID>15623544</PMID>
  </reference>
  <reference>
    <citation>Kim HW, Klem I, Shah DJ, Wu E, Meyers SN, Parker MA, Crowley AL, Bonow RO, Judd RM, Kim RJ. Unrecognized non-Q-wave myocardial infarction: prevalence and prognostic significance in patients with suspected coronary disease. PLoS Med. 2009 Apr 21;6(4):e1000057. doi: 10.1371/journal.pmed.1000057. Epub 2009 Apr 21.</citation>
    <PMID>19381280</PMID>
  </reference>
  <reference>
    <citation>Kato K, Yonetsu T, Kim SJ, Xing L, Lee H, McNulty I, Yeh RW, Sakhuja R, Zhang S, Uemura S, Yu B, Mizuno K, Jang IK. Nonculprit plaques in patients with acute coronary syndromes have more vulnerable features compared with those with non-acute coronary syndromes: a 3-vessel optical coherence tomography study. Circ Cardiovasc Imaging. 2012 Jul;5(4):433-40. doi: 10.1161/CIRCIMAGING.112.973701. Epub 2012 Jun 7.</citation>
    <PMID>22679059</PMID>
  </reference>
  <reference>
    <citation>Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z, Serruys PW; PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011 Jan 20;364(3):226-35. doi: 10.1056/NEJMoa1002358. Erratum in: N Engl J Med. 2011 Nov 24;365(21):2040.</citation>
    <PMID>21247313</PMID>
  </reference>
  <reference>
    <citation>Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH, Yeoh SE, Wallace W, Salter D, Fletcher AM, van Beek EJ, Flapan AD, Uren NG, Behan MW, Cruden NL, Mills NL, Fox KA, Rudd JH, Dweck MR, Newby DE. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet. 2014 Feb 22;383(9918):705-13. doi: 10.1016/S0140-6736(13)61754-7. Epub 2013 Nov 11.</citation>
    <PMID>24224999</PMID>
  </reference>
  <reference>
    <citation>Dweck MR, Chow MW, Joshi NV, Williams MC, Jones C, Fletcher AM, Richardson H, White A, McKillop G, van Beek EJ, Boon NA, Rudd JH, Newby DE. Coronary arterial 18F-sodium fluoride uptake: a novel marker of plaque biology. J Am Coll Cardiol. 2012 Apr 24;59(17):1539-48. doi: 10.1016/j.jacc.2011.12.037.</citation>
    <PMID>22516444</PMID>
  </reference>
  <reference>
    <citation>Kim RJ, Chen EL, Lima JA, Judd RM. Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation. 1996 Dec 15;94(12):3318-26.</citation>
    <PMID>8989146</PMID>
  </reference>
  <reference>
    <citation>Kwee RM, van Oostenbrugge RJ, Mess WH, Prins MH, van der Geest RJ, ter Berg JW, Franke CL, Korten AG, Meems BJ, van Engelshoven JM, Wildberger JE, Kooi ME. MRI of carotid atherosclerosis to identify TIA and stroke patients who are at risk of a recurrence. J Magn Reson Imaging. 2013 May;37(5):1189-94. doi: 10.1002/jmri.23918. Epub 2012 Nov 16.</citation>
    <PMID>23166040</PMID>
  </reference>
  <reference>
    <citation>Ambrose JA, Winters SL, Stern A, Eng A, Teichholz LE, Gorlin R, Fuster V. Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol. 1985 Mar;5(3):609-16.</citation>
    <PMID>3973257</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2015</study_first_submitted>
  <study_first_submitted_qc>September 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2015</study_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maastricht University Medical Center</investigator_affiliation>
    <investigator_full_name>Bas Bekkers</investigator_full_name>
    <investigator_title>M.D., Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>vulnerable plaque</keyword>
  <keyword>Positron emission tomography (PET)</keyword>
  <keyword>Cardiac magnetic resonance imaging (CMR)</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Non-ST Elevated Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

